ArticleTranslational vision science & technology2022
The Topographic Relationship Between Choroidal Microvascular Dropout and Glaucomatous Damage in Primary Angle-Closure Glaucoma.
Article in Translational vision science & technology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
- Swept-source optical coherence tomography quantitative scoring system accurately predicts postoperative intraocular pressure control and visual outcomes in primary angle-closure glaucoma.American journal of translational research · 2026Article
- Accuracy of new intraocular lens calculation formulas in primary angle closure glaucoma patients who underwent phacoemulsification combined with goniosynechialysis.International ophthalmology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To study the topographic relationship between parapapillary choroidal microvasculature dropout (MvD) and parapapillary retinal nerve fiber layer (RNFL) defect in primary angle-closure glaucoma (PACG) eyes. Methods: This cross-sectional study was carried out in a glaucoma clinic. Patients with PACG and healthy controls were consecutively enrolled. Each subject underwent optical coherence tomography angiography (OCTA) and OCT testing; additionally, visual field (VF) tests were also conducted in the patients with PACG. MvD was determined when choroidal layer images in OCTA showed a complete loss of the microvasculature. The study included 55 patients with PACG and 30 healthy controls. Results: Fifty-five eyes in 55 patients with PACG and 30 eyes in 30 healthy controls were recruited. MvD was found in 26 PACG eyes (47.3%), but no MvD was found in the healthy eyes. Compared with PACG eyes without MvD, eyes with MvD had thinner average RNFL (P < 0.001), worse VF mean deviation (P = 0.006), and lower peripapillary vessel density (P < 0.001). Between MvD and RNFL defects, there was good topographic consistency in angular circumference (Bland-Altman 95% confidence interval [CI], -24.9° to 21.0°) and position (Bland-Altman 95% CI, -18.6° to 20.6°). There was a significant correlation between the MvD angular circumference and the average peripapillary vessel density (r = -0.505; P = 0.014), average RNFL thickness (r = -0.742; P < 0.001), and VF mean deviation (r = -0.572; P = 0.004). Conclusions: In patients with PACG, the MvD angular circumference and position were highly topographic consistent with those of the peripapillary RNFL defect area. This study suggests that there is a significant correlation between MvD and glaucoma optic nerve injury. Translational Relevance: Given the vascular etiology for glaucoma, the current research suggests that the MvD angular circumference may serve as a potential supplementary clue of glaucoma disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.